Teprotumumab (Tepezza): from the Discovery and Development of Medicines to USFDA Approval for Active Thyroid Eye Disease (TED) Treatment

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2021 Jan 22

PMID 33481154

Citations 3

Authors

Faraat Ali

Anushma Chorsiya

Varisha Anjum

Asad Ali

Affiliations

Soon will be listed here.

Abstract

Teprotumumab (TPT) is a type I insulin-like growth factor receptor inhibitor, marketed as Tepezza; recently USFDA approved it for the treatment of thyroid eye disease (thyroid-associated ophthalmopathy (TAO), Graves ophthalmopathy/orbitopathy) in the USA. It is a monoclonal antibody although it was initially developed in collaboration with Genmab and Roche for the treatment of the tumour, but later it was investigated by River Vision Development Corporation and Horizon Therapeutics for its ophthalmic use. The drug has been designated as an orphan drug, breakthrough designation and fast-track designation. This review summarizes the milestones in the research and development including ongoing, clinical trial of TPT till now, foremost to this primary approval for thyroid-associated ophthalmopathy (TAO).

Citing Articles

Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.

Bocklud B, Fakhre W, Murphy B, Maddox K, Ahmadzadeh S, Viswanath O Cureus. 2023; 15(8):e43878.

PMID: 37746376 PMC: 10511347. DOI: 10.7759/cureus.43878.

MiR-143 Targets IGF-1R to Suppress Autoimmunity in Thyroid-Associated Ophthalmopathy.

Tang W, Lv Q, Huang X, Li Y, Zou J, Zheng J J Inflamm Res. 2022; 15:1543-1554.

PMID: 35256853 PMC: 8898058. DOI: 10.2147/JIR.S339483.

Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects.

Kang J, Lechuga M, Braun J, Kossler A, Douglas R, Cockerham K J Infus Nurs. 2021; 44(6):331-338.

PMID: 34753152 PMC: 10853843. DOI: 10.1097/NAN.0000000000000446.

References

Tencer J, Thysell H . [Wegener's granulomatosis--a retrospective study of 11 patients]. Lakartidningen. 1985; 82(3):113-5. View

Bahn R . Graves' ophthalmopathy. N Engl J Med. 2010; 362(8):726-38. PMC: 3902010. DOI: 10.1056/NEJMra0905750. View

Mellington F, Dayan C, Dickinson A, Hickey J, MacEwen C, McLaren J . Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. Orbit. 2017; 36(3):159-169. DOI: 10.1080/01676830.2017.1280057. View

Hodgson N, Rajaii F . Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review. Ophthalmol Ther. 2019; 9(1):21-33. PMC: 7054489. DOI: 10.1007/s40123-019-00226-9. View

Harris M, Realini T, Hogg J, Sivak-Callcott J . CT dimensions of the lacrimal gland in Graves orbitopathy. Ophthalmic Plast Reconstr Surg. 2012; 28(1):69-72. DOI: 10.1097/IOP.0b013e31823c4a3a. View

Eckstein A, Finkenrath A, Heiligenhaus A, Renzing-Kohler K, Esser J, Kruger C . Dry eye syndrome in thyroid-associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol Scand. 2004; 82(3 Pt 1):291-7. DOI: 10.1111/j.1395-3907.2004.00268.x. View

Razek A, Gaballa G, Denewer A, Tawakol I . Diffusion weighted MR imaging of the breast. Acad Radiol. 2009; 17(3):382-6. DOI: 10.1016/j.acra.2009.10.014. View

Razek A, Abd El-Gaber N, Abdalla A, Fathy A, Azab A, Abdel Rahman A . Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III. Neuroradiology. 2009; 51(11):773-9. DOI: 10.1007/s00234-009-0548-1. View

Razek A, Elkhamary S, Mousa A . Differentiation between benign and malignant orbital tumors at 3-T diffusion MR-imaging. Neuroradiology. 2011; 53(7):517-22. DOI: 10.1007/s00234-011-0838-2. View

10.

Sepahdari A, Politi L, Aakalu V, Kim H, Abdel Razek A . Diffusion-weighted imaging of orbital masses: multi-institutional data support a 2-ADC threshold model to categorize lesions as benign, malignant, or indeterminate. AJNR Am J Neuroradiol. 2013; 35(1):170-5. PMC: 4138308. DOI: 10.3174/ajnr.A3619. View

11.

Razek A, Sadek A, Gaballa G . Diffusion-weighed MR of the thyroid gland in Graves' disease: assessment of disease activity and prediction of outcome. Acad Radiol. 2010; 17(6):779-83. DOI: 10.1016/j.acra.2010.01.014. View

12.

Razek A, Abd Allah S, El-Said A . Role of Diffusion-Weighted Magnetic Resonance (MR) Imaging in Differentiation Between Graves' Disease and Painless Thyroiditis. Pol J Radiol. 2018; 82:536-541. PMC: 5894041. DOI: 10.12659/PJR.902416. View

13.

Heufelder A, Smith T, Gorman C, Bahn R . Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy. J Clin Endocrinol Metab. 1991; 73(2):307-13. DOI: 10.1210/jcem-73-2-307. View

14.

Bartalena L, Wiersinga W, Pinchera A . Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest. 2004; 27(3):295-301. DOI: 10.1007/BF03345280. View

15.

Smith T, Koumas L, Gagnon A, Bell A, Sempowski G, Phipps R . Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002; 87(1):385-92. DOI: 10.1210/jcem.87.1.8164. View

16.

Wiersinga W . Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?. J Clin Endocrinol Metab. 2011; 96(8):2386-94. DOI: 10.1210/jc.2011-0307. View

17.

Koumas L, Smith T, Phipps R . Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002; 32(2):477-85. DOI: 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U. View

18.

Sorisky A, Pardasani D, Gagnon A, Smith T . Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab. 1996; 81(9):3428-31. DOI: 10.1210/jcem.81.9.8784110. View

19.

Smith T, Bahn R, Gorman C, Cheavens M . Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. J Clin Endocrinol Metab. 1991; 72(5):1169-71. DOI: 10.1210/jcem-72-5-1169. View

20.

Cao H, Wang H, Zhang Y, Lin H, Phipps R, Smith T . Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated.... J Biol Chem. 1998; 273(45):29615-25. DOI: 10.1074/jbc.273.45.29615. View